Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression
- PMID: 7553651
Allelic losses on chromosomes 14, 10, and 1 in atypical and malignant meningiomas: a genetic model of meningioma progression
Abstract
To investigate chromosomal events that underlie formation and progression of meningiomas, we have examined a set of 18 benign (WHO grade I), 15 atypical (grade II), and 13 anaplastic/malignant (grade III) meningiomas for loss of heterozygosity (LOH) on chromosomes 1p, 6p, 9q, 10q, and 14q. Frequent loss of loci on these chromosomes was seen in grade II and grade III tumors, specifically, 14q (II and III, 47 and 55%), 1p (40 and 70%), and 10q (27 and 40%). In contrast, LOH for these loci was infrequent in benign meningiomas, specifically, 14q (0%), 1p (11%), and 10q (12%). The smallest common regions of deletion that could be defined were 14q24-q32, 1p32-pter, and 10q24-qter. These observations indicate the likely presence of tumor suppressor genes in these regions that are involved in the development of WHO grade II and grade III meningiomas. Because LOH for loci on chromosomes 1p and 10q was found in tumors of all grades and because the frequency of LOH in all three regions increased with tumor grade, these results would support a model for the formation of aggressive meningiomas through tumor progression.
Similar articles
-
NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas.Oncogene. 1999 Apr 1;18(13):2231-9. doi: 10.1038/sj.onc.1202531. Oncogene. 1999. PMID: 10327069
-
Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus.Oncogene. 1997 Feb 6;14(5):611-6. doi: 10.1038/sj.onc.1200853. Oncogene. 1997. PMID: 9053860
-
Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.Acta Neurol Belg. 2002 Jun;102(2):53-62. Acta Neurol Belg. 2002. PMID: 12161900
-
[The molecular genetics of meningiomas and genotypic/phenotypic correlations].Rev Neurol (Paris). 2003 Sep;159(8-9):727-38. Rev Neurol (Paris). 2003. PMID: 13679715 Review. French.
-
Molecular pathogenesis of meningiomas.J Neurooncol. 2004 Nov;70(2):183-202. doi: 10.1007/s11060-004-2749-0. J Neurooncol. 2004. PMID: 15674477 Review.
Cited by
-
Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9601-6. doi: 10.1073/pnas.0500404102. Epub 2005 Jun 27. Proc Natl Acad Sci U S A. 2005. PMID: 15983380 Free PMC article.
-
MEG3: a novel long noncoding potentially tumour-suppressing RNA in meningiomas.J Neurooncol. 2013 Mar;112(1):1-8. doi: 10.1007/s11060-012-1038-6. Epub 2013 Jan 11. J Neurooncol. 2013. PMID: 23307326 Review.
-
Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.Am J Pathol. 2002 Aug;161(2):665-72. doi: 10.1016/S0002-9440(10)64222-8. Am J Pathol. 2002. PMID: 12163391 Free PMC article.
-
Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas.Neuro Oncol. 2004 Oct;6(4):290-9. doi: 10.1215/S1152851704000158. Neuro Oncol. 2004. PMID: 15494096 Free PMC article.
-
Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade.Brain Pathol. 2011 Jan;21(1):57-73. doi: 10.1111/j.1750-3639.2010.00453.x. Brain Pathol. 2011. PMID: 21129060 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical